VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation

Francesco Autore; Daniele Mannina; Federica Lessi; Eugenio Galli; Stefania Oliva; Daniele Derudas; Claudia Giannotta; Claudia Crippa; Katia Mancuso; Magda Marcatti; Idanna Innocenti; Rita Mazza; Stefania Bramanti; Luca Laurenti

doi:10.1002/hon.70049

VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation

Francesco Autore^*
, Daniele Mannina
, Federica Lessi
, Eugenio Galli
, Stefania Oliva
, Daniele Derudas
, Claudia Giannotta
, Claudia Crippa
, Katia Mancuso
, Magda Marcatti
, Idanna Innocenti
, Rita Mazza
, Stefania Bramanti
, Luca Laurenti

^*Corresponding author

IRCCS Istituto Clinico Humanitas - Rozzano (Milano)
Azienda Ospedaliera di Padova
S. Giovanni Battista
SC di Ematologia e CTMO - Oncologico Oncologico di Riferimento Regionale “A. Businco” - ARNAS “G. Brotzu”
Spedali Civili Di Brescia
University of Bologna
Alma Mater Studiorum University of Bologna
San Raffaele Scientific Institute

Research output: Contribution to journal › Article

Abstract

Overproduction of vascular endothelial growth factor (VEGF) seems to contribute to the pathogenesis, still unclear, of POEMS Syndrome. Our study retrospectively reviewed the clinical and VEGF data from a multicenter Italian cohort of patients affected by POEMS syndrome who underwent to autologous peripheral blood stem cell transplantation (aPBSCT) in order to find an impact on clinical improvement or outcome. Patients with VEGF levels higher than 758 pg/mL were at higher risk of relapse, with sensible difference in PFS (p = 0.007). VEGF could be used as a marker of relapse and as a marker of disease intensity in patients with POEMS.

Original language	English
Pages (from-to)	N/A-N/A
Journal	Hematological Oncology
Volume	43
Issue number	2
DOIs	https://doi.org/10.1002/hon.70049
Publication status	Published - 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Hematology
Oncology
Cancer Research

Keywords

POEMS
VEGF
aPBSCT

Access to Document

10.1002/hon.70049

Cite this

Autore, F., Mannina, D., Lessi, F., Galli, E., Oliva, S., Derudas, D., Giannotta, C., Crippa, C., Mancuso, K., Marcatti, M., Innocenti, I., Mazza, R., Bramanti, S., & Laurenti, L. (2025). VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation. Hematological Oncology, 43(2), N/A-N/A. https://doi.org/10.1002/hon.70049

@article{4463764fef654bb9a91416a693001a38,

title = "VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation",

abstract = "Overproduction of vascular endothelial growth factor (VEGF) seems to contribute to the pathogenesis, still unclear, of POEMS Syndrome. Our study retrospectively reviewed the clinical and VEGF data from a multicenter Italian cohort of patients affected by POEMS syndrome who underwent to autologous peripheral blood stem cell transplantation (aPBSCT) in order to find an impact on clinical improvement or outcome. Patients with VEGF levels higher than 758 pg/mL were at higher risk of relapse, with sensible difference in PFS (p = 0.007). VEGF could be used as a marker of relapse and as a marker of disease intensity in patients with POEMS.",

keywords = "POEMS, VEGF, aPBSCT, POEMS, VEGF, aPBSCT",

author = "Francesco Autore and Daniele Mannina and Federica Lessi and Eugenio Galli and Stefania Oliva and Daniele Derudas and Claudia Giannotta and Claudia Crippa and Katia Mancuso and Magda Marcatti and Idanna Innocenti and Rita Mazza and Stefania Bramanti and Luca Laurenti",

year = "2025",

doi = "10.1002/hon.70049",

language = "English",

volume = "43",

pages = "N/A--N/A",

journal = "Hematological Oncology",

issn = "1099-1069",

publisher = "John Wiley and Sons Ltd",

number = "2",

}

Autore, F, Mannina, D, Lessi, F, Galli, E, Oliva, S, Derudas, D, Giannotta, C, Crippa, C, Mancuso, K, Marcatti, M, Innocenti, I, Mazza, R, Bramanti, S & Laurenti, L 2025, 'VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation', Hematological Oncology, vol. 43, no. 2, pp. N/A-N/A. https://doi.org/10.1002/hon.70049

TY - JOUR

T1 - VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation

AU - Autore, Francesco

AU - Mannina, Daniele

AU - Lessi, Federica

AU - Galli, Eugenio

AU - Oliva, Stefania

AU - Derudas, Daniele

AU - Giannotta, Claudia

AU - Crippa, Claudia

AU - Mancuso, Katia

AU - Marcatti, Magda

AU - Innocenti, Idanna

AU - Mazza, Rita

AU - Bramanti, Stefania

AU - Laurenti, Luca

PY - 2025

Y1 - 2025

N2 - Overproduction of vascular endothelial growth factor (VEGF) seems to contribute to the pathogenesis, still unclear, of POEMS Syndrome. Our study retrospectively reviewed the clinical and VEGF data from a multicenter Italian cohort of patients affected by POEMS syndrome who underwent to autologous peripheral blood stem cell transplantation (aPBSCT) in order to find an impact on clinical improvement or outcome. Patients with VEGF levels higher than 758 pg/mL were at higher risk of relapse, with sensible difference in PFS (p = 0.007). VEGF could be used as a marker of relapse and as a marker of disease intensity in patients with POEMS.

AB - Overproduction of vascular endothelial growth factor (VEGF) seems to contribute to the pathogenesis, still unclear, of POEMS Syndrome. Our study retrospectively reviewed the clinical and VEGF data from a multicenter Italian cohort of patients affected by POEMS syndrome who underwent to autologous peripheral blood stem cell transplantation (aPBSCT) in order to find an impact on clinical improvement or outcome. Patients with VEGF levels higher than 758 pg/mL were at higher risk of relapse, with sensible difference in PFS (p = 0.007). VEGF could be used as a marker of relapse and as a marker of disease intensity in patients with POEMS.

KW - POEMS

KW - VEGF

KW - aPBSCT

KW - POEMS

KW - VEGF

KW - aPBSCT

UR - https://publicatt.unicatt.it/handle/10807/313169

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85218694526&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85218694526&origin=inward

U2 - 10.1002/hon.70049

DO - 10.1002/hon.70049

M3 - Article

SN - 1099-1069

VL - 43

SP - N/A-N/A

JO - Hematological Oncology

JF - Hematological Oncology

IS - 2

ER -

VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this